JANSSEN CILAG SA

Their core work

Janssen Cilag SA is the Spanish arm of Janssen Pharmaceuticals (part of Johnson & Johnson), one of the world's largest pharmaceutical companies. Within H2020, they contribute industrial pharmaceutical R&D expertise to academic training networks and research projects focused on advanced chemistry methods — particularly photocatalysis, flow chemistry, and computational drug discovery. Their role is to provide real-world drug development context and industrial placements for early-stage researchers, bridging the gap between academic chemistry innovation and pharmaceutical manufacturing needs.

What they specialise in

How they've shifted over time

In the early period (2015-2018), Janssen Cilag engaged broadly across pharmaceutical chemistry — from continuous-flow photoredox catalysis (Photo4Future) to large-scale computational drug screening (ExCAPE) and fluorination chemistry (FLUDD). By the recent period (2021-2025), their focus has sharpened significantly toward photocatalysis applied to synthetic organic chemistry, with explicit emphasis on photoreactor design, flow chemistry, and mechanistic understanding. This narrowing suggests they found strategic value in photocatalytic methods and are now investing deeper in making these production-ready.

Janssen Cilag is converging on photocatalytic flow chemistry as a scalable tool for pharmaceutical synthesis, moving from exploratory participation toward reactor-level implementation.

How they like to work

Janssen Cilag operates exclusively as a participant, never leading consortia — consistent with a large pharma company that joins academic training networks to scout talent and emerging methods rather than to drive project agendas. With 32 unique partners across 17 countries in just 4 projects, they engage in large, diverse consortia typical of MSCA training networks. This makes them an accessible but selective partner: they bring industrial scale and pharmaceutical application context, but expect the academic side to lead.

Across 4 projects, Janssen Cilag has collaborated with 32 distinct partners in 17 countries, reflecting the broad international consortia typical of MSCA training networks. Their network spans most of Europe without a strong geographic concentration beyond their Spanish base.

What sets them apart

As a major pharmaceutical company, Janssen Cilag offers something most academic partners cannot: a direct pipeline from lab-scale chemistry research to industrial drug manufacturing. Their consistent focus on photocatalysis and flow chemistry across nearly a decade of projects shows genuine strategic interest, not token participation. For academic groups developing new synthetic methods, partnering with Janssen provides both industrial validation and a realistic path to pharmaceutical application.

Highlights from their portfolio

• ExCAPE
  Largest funded project (EUR 448K) and a departure from their chemistry focus — tackling exascale computational prediction of compound activity, showing their data-driven drug discovery ambitions.
• PhotoReAct
  Most recent project (2021-2025) with detailed keywords, representing the clearest signal of their current strategic direction toward photocatalytic reactor technology.
• FLUDD
  Directly targets late-stage fluorination for drug discovery — the most explicitly pharma-applied project, connecting academic chemistry to real pharmaceutical manufacturing needs.